209 related articles for article (PubMed ID: 30201098)
1. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.
To M; Kono Y; Yamawaki S; Soeda S; Katsube O; Kishi H; To Y
J Allergy Clin Immunol Pract; 2018; 6(5):1746-1748.e1. PubMed ID: 30201098
[No Abstract] [Full Text] [Related]
2. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
[No Abstract] [Full Text] [Related]
3. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
4. Benralizumab as initial treatment for chronic eosinophilic pneumonia.
Yazawa S; Toyoshima M; Koda K; Suda T
Allergol Int; 2021 Jan; 70(1):140-142. PubMed ID: 32807690
[No Abstract] [Full Text] [Related]
5. Mepolizumab use: Post-approval academic practice experience.
Benjamin MR; Bochner BS; Peters AT
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
[No Abstract] [Full Text] [Related]
6. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
7. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro M; Bacharier LB
Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
[No Abstract] [Full Text] [Related]
8. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.
Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H
J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319
[No Abstract] [Full Text] [Related]
9. Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab.
Ricketti PA; Ricketti AJ
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):726-727. PubMed ID: 33636343
[No Abstract] [Full Text] [Related]
10. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
Weir E; Paton J
J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
[No Abstract] [Full Text] [Related]
11. Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.
Brenard E; Pilette C; Dahlqvist C; Colinet B; Schleich F; Roufosse F; Froidure A
Lung; 2020 Apr; 198(2):355-360. PubMed ID: 32052155
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
[TBL] [Abstract][Full Text] [Related]
13. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
Cormier M; Chaboillez S; Lemiere C
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
[No Abstract] [Full Text] [Related]
14. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
Haldar P; Brightling CE; Singapuri A; Hargadon B; Gupta S; Monteiro W; Bradding P; Green RH; Wardlaw AJ; Ortega H; Pavord ID
J Allergy Clin Immunol; 2014 Mar; 133(3):921-3. PubMed ID: 24418480
[No Abstract] [Full Text] [Related]
15. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
16. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
[No Abstract] [Full Text] [Related]
17. Mepolizumab (Nucala) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
[No Abstract] [Full Text] [Related]
18. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
Kurosawa M; Sutoh E
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
[No Abstract] [Full Text] [Related]
19. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
Drick N; Seeliger B; Welte T; Fuge J; Suhling H
BMC Pulm Med; 2018 Jul; 18(1):119. PubMed ID: 30021546
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
Albers FC; Price RG; Smith SG; Yancey SW
J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
[No Abstract] [Full Text] [Related]
[Next] [New Search]